Study objective-To assess the effectiveness of inhibition of angiotensin converting enzyme in preventing diabetic nephropathy.
End point-Albumin excretion, arterial pressure, and renal function.
Main results-In last three months of trial three of 10 patients taking placebo had diabetic nephropathy (albumin excretion >300 mg/24 hours). No patients taking enalapril developed nephropathy and five showed normal albumin excretion (<30 mg/24 hours) (p=0O005, Mann-Whitney test). Mean arterial pressure was reduced by enalapril throughout study (p<0005) but increased linearly with placebo (p<005). Albumin excretion decreased linearly with enalapril but not placebo. An increase in albumin excretion with placebo was positively related to the increase in mean arterial pressure (r=0.709, p<005, Spearman's rank test). With enalapril total renal resistances and fractional albumin clearances improved progressively (time effect, p=0.0001).
Conclusion-Inhibition of angiotensin converting enzyme prevents development of nephropathy in normotensive diabetics with persistent microalbuminuria. This may be due to reduction in intraglomerular pressure and to prevention of increased systemic blood pressure. Future studies should compare long term effects of inhibitors of converting enzyme with other antihypertensive drugs. Service de Diabetologie,
Introduction
Diabetic nephropathy is defined as the onset of persistent proteinuria with raised blood pressure in patients with chronic diabetes mellitus.' The life expectancy in such patients is reduced by a high risk of renal failure or cardiovascular disease, or both.' 2 The condition is preceded by incipient diabetic nephropathy,3 which is characterised by persistent microalbuminuria -that is, an albumin excretion rate above normal values but below those giving positive results on dipstick testing. Abnormalities of the haemodynamics within the kidney, resulting in glomerular hyperfiltration, can be detected from the onset of diabetes and may be determinants in the development of diabetic nephropathy. 45 Several types of intervention have been proposed to prevent the onset of persistent proteinuria in diabetics. Strict metabolic control achieved with portable insulin pumps can reverse glomerular hyperfiltration due to poor metabolic control,6 but at least two years' treatment must be given to prevent diabetic nephropathy from developing. Also the selection criteria proposed for this treatment make large scale treatment of insulin dependent diabetics difficult. After a three month pretreatment period the patients were allocated in pairs to receive treatment for one year with either 20 mg enalapril daily or its matched placebo. The randomisation schedule and the instructions given to the patients have been reported." The patients were entered into the study over six months. The 10 patients entered into the trial first were followed up double blind; two had persistent proteinuria and blood pressures above 140/90 mm Hg at the end of the one year treatment. As antihypertensive treatment must be instituted promptly in such patients'4-'6 the double blind code was disrupted, and the two patients, who had been treated with placebo, were given antihypertensive drugs. Therefore, the last 10 patients recruited were followed up 
Median (range) urinary sodium (mmol/24h): 8-3(4-6-11-5) 7-6(4-3-11-2) Enalapril 6-6(4-8-10-2) 6-7(4-6-11-0) 7 6(5-1-9-7)
Mean (range) haemoglobin (%): Placebo 8-2 (6-2-9-6) 8-4 (7-2-10-5) 8-8 (7-0-9-7) Enalapril 8-1 (7-0-9-7) 8-3 (6-6-11-4) 8-3 (7 2-9-8) Mean (range) active renin (pmol/l): In our study albumin excretion and mean arterial pressure rose in parallel during treatment with placebo for one year and were significantly correlated. This is consistent with observations on similar patients who did not receive antihypertensive treatment for two years,7 but in both studies the diabetics with persistent microalbuminuria and hypertension were eliminated. Thus too few patients with persistent microalbuminuria were studied to estimate the incidence of diabetic nephropathy. Also the means by which inhibition of converting enzyme can modify this incidence requires studies ofmany patients. Nevertheless, microalbuminuria in diabetics is associated with a significant increase in blood pressure compared with controls.3 32 Taken together these data support the view that a slight rise in blood pressure occurs in diabetics together with microalbuminuria progressing to macroalbuminuria and suggest that antihypertensive treatment should be instituted early in diabetics compared with normoglycaemic hypertensive patients. 33 We cannot conclude from our results whether the observed reduction in albumin excretion can be related to reduction of blood pressure systemically or to reduction of that within the glomeruli specifically due to inhibition of the converting enzyme. In azotemic diabetics the addition of captopril to conventional antihypertensive treatment has been claimed to give short term reduction in heavy proteinuria without any further reduction in blood pressure. 34 On the other hand, another study on treatment of hypertension with captopril in diabetic nephropathy showed that a reduction in urinary albumin excretion was accompanied by a reduction in blood pressure.35 In non-diabetic rats proteinuria due to hypertension was prevented by enalapril but not by conventional antihypertensive triple treatment, though blood pressure was reduced equally in both treatments.36 Conversely, Bank et al presented experimental evidence against the hypothesis of increased glomerular pressure as a determinant in initiating diabetic nephropathy but showed in the same study that lowering blood pressure to hypotensive values in diabetic rats protected against early diabetic nephropathy. 37 No data are yet available in human diabetics in favour of a beneficial effect of inhibition of converting enzyme on albumin excretion independently of its hypotensive effect. Studies in diabetics with microalburninuria should compare the long term effects of inhibitors ofangiotensin converting enzyme with those of other antihypertensive drugs.
